

# Hendrik Rathke

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4860585/publications.pdf>

Version: 2024-02-01

30  
papers

2,762  
citations

331538

21  
h-index

454834

30  
g-index

31  
all docs

31  
docs citations

31  
times ranked

2156  
citing authors

#	ARTICLE	IF	CITATIONS
1	First patient exceeding 5-year complete remission after 225Ac-PSMA-TAT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 311-312.	3.3	18
2	Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 113-122.	3.3	72
3	Impact of <sup>68</sup> Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas. <i>Journal of Nuclear Medicine</i> , 2021, 62, 779-786.	2.8	113
4	[153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3011-3013.	3.3	60
5	The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4067-4076.	3.3	20
6	The role of combined ion-beam radiotherapy (CIBRT) with protons and carbon ions in a multimodal treatment strategy of inoperable osteosarcoma. <i>Radiotherapy and Oncology</i> , 2021, 159, 8-16.	0.3	21
7	<sup>68</sup> Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas – Imaging analysis and histological validation. <i>Radiotherapy and Oncology</i> , 2021, 160, 192-201.	0.3	40
8	Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 54-63.	3.3	35
9	Two Tumors, One Target. <i>Clinical Nuclear Medicine</i> , 2021, 46, 842-844.	0.7	30
10	Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. <i>Lancet Oncology</i> , The, 2021, 22, 1115-1125.	5.1	120
11	Patients Resistant Against PSMA-Targeting ±-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes. <i>Journal of Nuclear Medicine</i> , 2020, 61, 683-688.	2.8	61
12	Response Prediction of <sup>177</sup> Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase. <i>Journal of Nuclear Medicine</i> , 2020, 61, 689-695.	2.8	39
13	Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. <i>European Urology</i> , 2020, 78, 148-154.	0.9	39
14	The Role of <sup>68</sup> Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1331-1336.	2.8	106
15	FAP-specific PET signaling shows a moderately positive correlation with relative CBV and no correlation with ADC in 13 IDH wildtype glioblastomas. <i>European Journal of Radiology</i> , 2020, 127, 109021.	1.2	28
16	Prognostic markers for overall survival and outcome to LuPSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5548-5548.	0.8	1
17	Efficacy and safety of 177Lu-PSMA radionuclide treatment in patients with diffuse bone marrow involvement: A multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17543-e17543.	0.8	1
18	Validating the Xerostomia Inventory in a radiation-induced xerostomia population in German language. <i>Oral Diseases</i> , 2019, 25, 1744-1750.	1.5	13

#	ARTICLE	IF	CITATIONS
19	FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1754-1755.	3.3	58
20	<sup>68</sup> Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 801-805.	2.8	874
21	Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing <sup>225</sup> Ac-PSMA-617 RLT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 139-147.	3.3	72
22	Dosimetry Estimate and Initial Clinical Experience with <sup>90</sup> Y-PSMA-617. <i>Journal of Nuclear Medicine</i> , 2019, 60, 806-811.	2.8	27
23	Targeted $\alpha$ -Therapy of Metastatic Castration-Resistant Prostate Cancer with <sup>225</sup> Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control. <i>Journal of Nuclear Medicine</i> , 2018, 59, 795-802.	2.8	322
24	Intraindividual Comparison of <sup>99m</sup> Tc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand <sup>99m</sup> Tc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1373-1379.	2.8	31
25	[ <sup>18</sup> F]PSMA-1007 PET Improves the Diagnosis of Local Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History of Bilateral Hip Arthroplasty. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 111-113.	0.9	4
26	Targeted alpha therapy of mCRPC: Dosimetry estimate of <sup>213</sup> Bismuth-PSMA-617. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 31-37.	3.3	107
27	Repeated <sup>177</sup> Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq. <i>Journal of Nuclear Medicine</i> , 2018, 59, 459-465.	2.8	68
28	Impact of sialendoscopy on improving health related quality of life in patients suffering from radioiodineinduced xerostomia. <i>Nuklearmedizin - NuclearMedicine</i> , 2018, 57, 160-167.	0.3	6
29	Targeted $\alpha$ -Therapy of Metastatic Castration-Resistant Prostate Cancer with <sup>225</sup> Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1624-1631.	2.8	367
30	Integration of CT urography improves diagnostic confidence of <sup>68</sup> Ga-PSMA-11 PET/CT in prostate cancer patients. <i>Cancer Imaging</i> , 2017, 17, 30.	1.2	8